Abstract
We recently reported that IgM MAb B6.1, specific for β-1, 2-mannotriose on the cell wall of Candida albicans, is therapeutic to disseminated candidiasis due to C. albicans. In the current study, we examined if MAbB6.1 enhances therapeutic effect of fluconazole (FLC) to the disseminated disease. To assess the combination effect, determination by the kidneys-colony forming unit and survival times were used. Results showed that the therapeutic effect of FLC on mice with disseminated candidiasis was dose-dependent, but a FLC dose at 0.8 mg/kg body weight of mice was ineffective. To determine combination effect, mice treated intraperitoneally with a combination of FLC plus MAb B6.1 at 1 h post-infection — a condition of developing partial therapeutic activity — enhanced survival times beyond the effect by only antibody (p < 0.05). The resulting MST (mean survival times) value from the combinationreceived mice was almost the same as MST value from 3.2 mg FLC dose-given animals (p < 0.05). Another combination of 1.6 mg FLC dose and B6.1 reduced severity of the disseminated disease at almost the same rate as combination efficacy of 0.8 mg FLC dose plus B6.1. This data indicates that B6.1 acts in concert with FLC and that this combination therapy augments protection, which suggests a possibility of reducing FLC dose. The augmentation response was specific because an irrelevant IgM MAb S9 was not effective to the disseminated disease. Thus, our present studies demonstrate that this combination immunotherapy may be a way of solving the problem of limited antifungal drug choices caused by drug-resistant C. albicans.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antachopoulos, C., Walsh, T. J., and Roilides, E., Fungal infections in primary immunodeficiencies. Eur. J. Pediatr., 166, 1099–1117 (2007).
Bodey, G. P., The emergence of fungi as major hospital pathogens. J. Hosp. Infect., 11Suppl A, 411–426 (1988).
Brawner, D. L. and Cutler, J. E., Ultrastructural and biochemical studies of two dynamically expressed cell surface determinants on Candid albicans. Infect. Immun., 51, 327–336 (1986).
Caesar-TonThat, T. C. and Cutler, J. E., A monoclonal antibody to Candida albicans enhances mouse neutrophil candidacidal activity. Infect. Immun., 65, 5354–5357 (1997).
Dixon, T. C., Steinbach, W. J., Benjamin, D. K. Jr., Williams, L. W., and Myers, L. A., Disseminated Candida tropicalis in a patient with chronic mucocutaneous candidiasis. South Med. J., 97, 788–790 (2004).
Edwards, J. E., Invasive Candida infections: evolution of a fungal pathogen. N. Engl. J. Med., 324, 1060–1072 (1991).
Edwards, J. E., Bodey, G. P., Boeden, R. A., Buchner, T., DePauw, B. E., Filler, S. G., Ghannoum, M. A., Glauser, M., Herbrecht, R., Kauffman, C. A., Kohno, S., Martino, P., Meunier, F., Mori, T., Pfaller, M. A., Rex, J. H., Rogers, T. R., Rubin, R. H., Solomkin, J., Viscoli, C., Walsh, T. J., and White, M., International conference for the development of a consensus on the management and prevention of severe candidalinfections. Clin. Infect. Dis., 25, 43–59 (1997).
Epstein, J. B. and Polsky, B., Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies. Clin. Ther., 20, 40–57 (1998).
Filler, S. G. and Edwards, J. E., When and how to treat serious candidial infections: concepts and controversies. Curr. Clin. Top. Infect. Dis., 15, 1–18 (1995).
Fisher-Hoch, S. P. and Hutwagner, L., Opportunisticcandidiasis: an epidemic of the 1980s. Clin. Infect. Dis., 21, 897–904 (1995).
Fonos, V. and Cataldi, L., Amphotericin B-induced nephrotoxicity: a Review. J. Chemother., 12, 463–470 (2000).
Graybill, J. R., Editorial response: can we agree on the treatment of candidiasis? Clin. Infect. Dis., 25, 60–62 (1997).
Gupta, A. K., Sauder, D. N., and Shear, N. H., Antifungal agents: an overview. Part II. Am. Acad. Dermatol., 30, 911–933 (1994).
Gupta, A. K., Katz, H. I., and Shear, N. H., Drug interactions with itraconazole, fluconazole, and terbinafine and their management. J. Am. Acad. Dermatol., 41, 237–249 (1999).
Han, Y. and Cutler, J. E., Antibody response that protects against disseminated candidasis. Infect. Immun., 63, 2714–2719 (1995).
Han, Y. and Cutler, J. E., Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals. J. Infect. Dis., 15, 1169–1175 (1997).
Han, Y., Kanbe, T., Cherniak, R., and Cutler, J. E., Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect. Immun., 65, 4100–4107 (1997).
Han, Y., Morrison, R. P., and Cutler, J. E., A vaccine and monoclonal antibodies that Enhance mouse resistance to Candida albicans vaginal infection. Infect. Immun., 66, 5771–5776 (1998).
Han, Y., Riesselman, M., and Cutler, J. E., Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect. Immun., 68, 1649–1654 (2000).
Han, Y., Kozel, T. R., Zhang, M. X., MacGill, R. S., Carroll, M. C., and Cutler, J. E., Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J. Immunol., 67, 1550–1557 (2001).
Han, Y. and Lee, J. H., Berberine synergy with amphotericin B against disseminated candidiasis in mice. Biol. Pharm. Bull., 28, 541–544 (2005).
Han, Y., Synergic anticandidal effect of epigallocatechin-Ogallate combined with amphotericin B in a murine model of disseminated candidiasis and its anticandidal mechanism. Biol. Pharm. Bull., 30, 1693–1696 (2007).
Han, Y., Efficacy of combination immunotherapy of IgM MAb B6.1 and amphotericin B against disseminated candidiasis. Int. Immunopharmacol., 10, 1526–1531 (2010).
Jin, J., Guo, N., Zhang, J., Ding, Y., Tang, X., Liang, J., Li, L., Deng, X., and Yu, L., The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans. Lett. Appl. Microbiol., 51, 351–357 (2010).
Kofla, G., Turner, V., Schulz, B., Storch, U., Froelich, D., Rognon, B., Coste, A. T., Sanglard, D., and Ruhnke, M., Doxorubicin induces drug efflux pumps in Candida albicans. Med. Mycol., 49, 132–142 (2011).
MacNeill, C., Weisz, J., and Carey, J. C., Clinical resistance of recurrent Candida albicans vulvovaginitis to fluconazole in the presence and absence of in vitro resistance. J. Reprod. Med., 48, 63–68 (2003).
Masia Canuto, M. and Gutierrez Rodero, F., Antifungal drug resistance to azoles and polyenes. Lancet Infect. Dis., 2, 550–563 (2002).
Mayer, J., Doubek, M., Doubek, J., Horky, D., Scheer, P., and Stepanek, M., Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J. Infect. Dis., 186, 379–388 (2002).
Pincus, S. H., Cole, R. L., Kamanga-Sollo, E., and Fischer, S. H., Interaction of group B steptococcal opacity variants with the host defense system. Infect. Immun., 61, 3761–3768 (1993).
Rex, J. H., Walsh, T. J., and Anaissie, E. J., Fungal infections in iatrogenically compromised hosts. Adv. Intern. Med., 43, 321–371 (1998).
Sanglard, D., Clinical relevance of mechanism of antifungal drug resistance in yeasts. Enferm. Infecc. Microbiol. Clin., 20, 462–469 (2002).
Schaberg, D. R., Culver, D. H., and Gayner, R. P., Major trends in the microbial etiological nosocomial infection. Am. J. Med., 16, 72–75 (1991).
Sieck, T. G., Moors, M. A., Buckley, H. R., and Blank, K. J., Protection against murine disseminated candidiasis mediated by a Candida albicans-specific T-cell line. Infect. Immun., 61, 3540–3543 (1993).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, JH., Jang, EC. & Han, Y. Combination immunotherapy of MAb B6.1 with fluconazole augments therapeutic effect to disseminated candidiasis. Arch. Pharm. Res. 34, 399–405 (2011). https://doi.org/10.1007/s12272-011-0307-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-011-0307-9